Johnson & Johnson to release ?Transitions? contact lenses

The FDA-approved lenses, part of the Acuvue Oasys range and developed in partnership with Transitions Optical, contain a photochromic additive that controls the amount of visible light entering the eye, and also offers protection against exposure to blue and UV light.{{quote-a:r-w:420-I:2-Q:“After more than a decade of product development and numerous clinical trials involving more than 1,000 patients, we are excited to bring to market a solution to help contact lens wearers manage the changing light conditions they face every day.”-WHO:Dr Xiao-Yu Song, global head of R&D for Johnson & Johnson Vision}}“This innovation was born out of deep research into consumer lifestyle needs and fits our future-forward approach to caring for human sight. Acuvue Oasys with Transitions creates and defines an entirely new category of contact lenses that will address unmet needs for patients,” global head of R&D for Johnson & Johnson Vision Dr Xiao-Yu Song said.“After more than a decade of product development and numerous clinical trials involving more than 1,000 patients, we are excited to bring to market a solution to help contact lens wearers manage the changing light conditions they face every day in their modern, active lives.”The two-week reusable, spherical contact lenses are designed to correct myopia, hyperopia, and can be used by people with certain degrees of astigmatism.According to the FDA, it reviewed scientific evidence including a clinical study of 24 patients that evaluated daytime and night driving performance while wearing the contact lenses. The results of the study donstrated there was no evidence of concerns with either driving performance or vision while wearing the lenses.The lenses are expected to become commercially available in the first half of 2019.Image courtesy: Freepik